Poster Presentations Session II
Poster Presentations Session II Sunday, 17 September 2017
POSTERS SET-UP: 7:45 - 8:00
POSTERS DISPLAY HOURS: 8:00 - 14:00
POSTER AUTHOR DISCUSSION: 13:00 - 14:00
POSTERS DISMANTLE: 14:00


Poster display locations are shown below the poster codes
MUSCULAR-SKELETAL DISORDERS - Clinical Outcomes Studies
PMS1
K17
TREATMENT INTERRUPTION OF BIOLOGICAL DRUGS IN RHEUMATOID ARTHRITIS: AN ASSESSMENT OF CASE-REPORTS
Wiens A1, Borba HH2, Leonart L2, Ferreira VL1, Steimbach LM2, Tonin FS1, Araújo AG2, Piazza T1, Pontarolo R2
1Universidade Federal do Paraná, Curitiba, Brazil, 2Federal University of Parana, Curitiba, Brazil

PMS2
WITHDRAWN

PMS3
K18
SECUKINUMAB PROVIDES GREATER SYMPTOMATIC IMPROVEMENT VERSUS ADALIMUMAB IN PSORIATIC ARTHRITIS: COMPARATIVE EFFECTIVENESS UP TO 48 WEEKS ASSESSED BY TWO MATCHING-ADJUSTED INDIRECT COMPARISONS
Thom H1, Hunger M2, Rosal GF3, Gandhi K4, Jugl SM5, Nash P6
1University of Bristol, Bristol, UK, 2Mapi Group, Munich, Germany, 3Novartis Biociências SA, Sao Paulo, Brazil, 4Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA, 5Novartis Pharma AG, Basel, Switzerland, 6University of Queensland, Brisbane, Australia

PMS4
L1
COMPARATIVE EFFECTIVENESS OF SECUKINUMAB AND ADALIMUMAB IN ANKYLOSING SPONDYLITIS AS ASSESSED BY MATCHING-ADJUSTED INDIRECT COMPARISON: AN ANALYSIS BASED ON ALL PIVOTAL PHASE 3 CLINICAL TRIAL DATA
Maksymowych WP1, Walsh J2, Thom H3, Kalyvas C4, Rosal GF5, Porter B6, Gandhi K6, Jugl SM7
1University of Alberta, Edmonton, AB, Canada, 2University of Utah, Salt Lake City, UT, USA, 3University of Bristol, Bristol, UK, 4Mapi Group, Houten, The Netherlands, 5Novartis Biociências SA, Sao Paulo, Brazil, 6Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA, 7Novartis Pharma AG, Basel, Switzerland

PMS5
L2
SECUKINUMAB SHOWS GREATER SYMPTOMATIC IMPROVEMENT VERSUS INFLIXIMAB IN PSORIATIC ARTHRITIS: COMPARATIVE EFFECTIVENESS UP TO 1 YEAR ASSESSED BY MATCHING-ADJUSTED INDIRECT COMPARISONS
Strand V1, McInnes I2, Thom H3, Hunger M4, Lopes N5, Gandhi K6, Jugl SM7
1Stanford University, Stanford, CA, USA, 2University of Glasgow, Glasgow, UK, 3University of Bristol, Bristol, UK, 4Mapi Group, Munich, Germany, 5Novartis Biociências SA, Sao Paulo, Brazil, 6Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA, 7Novartis Pharma AG, Basel, Switzerland

PMS6
L3
SECUKINUMAB SHOWS GREATER SYMPTOMATIC IMPROVEMENT VERSUS ETANERCEPT IN PSORIATIC ARTHRITIS: COMPARATIVE EFFECTIVENESS UP TO 24 WEEKS ASSESSED BY MATCHING-ADJUSTED INDIRECT COMPARISON
Mease P1, Choy E2, Thom H3, Kalyvas C4, Lopes N5, Pricop L6, Gandhi K6, Jugl SM7, Nash P8
1Swedish Medical Center and University of Washington, Seattle, WA, USA, 2Cardiff University, Cardiff, UK, 3University of Bristol, Bristol, UK, 4Mapi Group, Houten, The Netherlands, 5Novartis Biociências SA, Sao Paulo, Brazil, 6Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA, 7Novartis Pharma AG, Basel, Switzerland, 8University of Queensland, Brisbane, Australia

PMS7
L4
IMPACT OF SPIRONOLACTONE ON DAS-28 IN NAIVE RHEUMATOID ARTHRITIS PATIENTS
Prajapati SK1, Iqbal MZ1, Ali AN1, Tahir M2, Khan AF3
1Aimst University, Sungai Petani, Malaysia, 2University of Veterinary and Animal Sciences, Lahore Pakistan, Lahore, Pakistan, 3University College of Pharmacy PU Lahore, Lahore, Pakistan

PMS8
L5
AMELIORATIVE EFFECT OF MORIN, A BIOFLAVONOID ON FREUND’S ADJUVANT INDUCED ESTABLISHED POLYARTHRITIS IN RATS
Mukherjee A, Kandhare AD, Bodhankar SL
Poona College of Pharmacy, Bharati Vidyapeeth Deemed University, Pune, Maharashtra, India

MUSCULAR-SKELETAL DISORDERS - Cost Studies
PMS9
L6
COST-SAVINGS DUE TO IMPLEMENTATION OF A SCREENING ALGORITHM FOR DIAGNOSIS OF RHEUMATOID ARTHIRITS IN COLOMBIA
Santos-Moreno P1, Villarreal Peralta L1, Jaimes H1, Jaimes J1, Buitrago-Garcia D2, Castro C2
1Biomab, center for rheumatoid arthritis, bogota, Colombia, 2SIIES investigation and research, Colombia, bogota, Colombia

PMS10
L7
IMPACTO ORÇAMENTÁRIO DA INCORPORAÇÃO DE TOFACITINIBE NO SISTEMA ÚNICO DE SAÚDE
Alexandre RF, Santana CF, Squiassi HB
Pfizer, São Paulo, Brazil

PMS11
L8
ANALYSIS OF THE BUDGET IMPACT OF SECUKINUMAB USE VERSUS ANTI-TNF AGENTS IN ANKYLOSING SPONDYLITIS PATIENTS
Romero Prada ME, Roa Cardenas NC, Serrano GY, Huerfano LM
Salutia Foundation - Research center in economy, management and health technologies., Bogota, Colombia

PMS12
L9
BUDGET IMPACT ANALYSIS OF TOCILIZUMAB, INFLIXIMAB AND ETANERCEPT DRUGS FOR THE TREATMENT OF RHEUMATOID ARTHRITIS IN ECUADOR
Briceno V1, Naranjo F2, Moscoso JD2, Salazar D2
1Massachusetts College of Pharmacy & Health Sciences, Boston, MA, Ecuador, 2Hospital Eugenio Espejo, Quito, Ecuador

PMS13
WITHDRAWN

PMS14
L10
COST-SAVINGS DUE TO THE WITHDRAWING OF BIOLOGICAL THERAPY FOR TREATMENT OF RHEUMATHOID ARTRITIS IN A SPECIALIZED CENTER IN COLOMBIA
Santos-Moreno P1, Villarreal Peralta L1, Jaimes H1, Jaimes J1, Buitrago-Garcia D2, Castro C2
1Biomab, center for rheumatoid arthritis, bogota, Colombia, 2SIIES investigation and research, Colombia, bogota, Colombia

PMS15
L11
ANÁLISE DE CUSTO MINIMIZAÇÃO NA SUBSTITUIÇÃO DE INFLIXIMABE POR SEU BIOSSIMILAR NO SISTEMA DE SAÚDE SUPLEMENTAR BRASILEIRO
Alexandre RF, Santana CF, Squiassi HB
Pfizer, São Paulo, Brazil

PMS16
L12
SECUKINUMAB SHOWS HIGHER SYMPTOMATIC IMPROVEMENT AND LOWER COST PER RESPONSE VS. ADALIMUMAB AFTER ONE YEAR TREATMENT OF ACTIVE ANKYLOSING SPONDYLITIS: A COST PER RESPONDER ANALYSIS FROM A CHILEAN PERSPECTIVE
Rojas R1, Barbeau M2, Jugl SM3, MacPherson A4
1Pontificia Universidad Catolica de Chile, Santiago, Chile, 2Novartis Pharmaceuticals Canada Inc., Dorval, QC, Canada, 3Novartis Pharma AG, Basel, Switzerland, 4Dalhousie University, Halifax, NS, Canada

PMS17
L13
SECUKINUMAB VS ADALIMUMAB FOR THE TREATMENT OF PSORIATIC ARTHRITIS: A COST PER RESPONDER ANALYSIS AT 48 WEEKS FROM A CHILEAN PERSPECTIVE
Rojas R1, Barbeau M2, Jugl SM3, MacPherson A4
1Pontificia Universidad Catolica de Chile, Santiago, Chile, 2Novartis Pharmaceuticals Canada Inc., Dorval, QC, Canada, 3Novartis Pharma AG, Basel, Switzerland, 4Dalhousie University, Halifax, NS, Canada

PMS18
L14
CONVENTIONAL AND BIOLOGICAL THERAPY IN PATIENTS WITH RHEUMATOID ARTHRITIS. A COST ANALYSIS IN COLOMBIA
Santos-Moreno P1, Villarreal Peralta L1, Alvis-Zakzuk NJ2, Jaimes Trespalacios H1, Carrasquilla Sotomayor M3, Jaimes Trespalacios J1, Alvis Guzman N4
1Biomab, center for rheumatoid arthritis, bogota, Colombia, 2ALZAK Foundation, Cartagena, Colombia, 3Alzak Foundation. Universidad de Cartagena., Cartagena de Indias, Colombia, 4ALZAK Foundation. Universidad de Cartagena., Cartagena de Indias, Colombia

PMS19
L15
COST BENEFIT ANALYSIS IN THE TREATMENT OF SEVERE OSTEOPOROSIS FROM THE PUBLIC HEALTHCARE SYSTEM PERSPECTIVE IN MEXICO
Carlos F1, Botello BS2, Lozano ME3
1Rac Salud Consultores, Mexico City, Mexico, 2Eli Lilly and Company, Mexico City, Mexico, 3Secretaría de Salud, Mexico City, Mexico

PMS20
L16
COST-EFFECTIVENES ANALYSIS OF ANTI-TNF USE COMPARED TO DMARDS IN THE FATAL AND NONFATAL ACUTE CORONARY ISCHEMIC EVENT.
Gomes RK1, Viscondi JY2, Nobre MR2
1Center of medical specialties of Brusque and Blumenau, Blumenau, Brazil, 2Universidade de São Paulo, São Paulo, Brazil

PMS21
L17
SECUKINUMAB VS ADALIMUMAB FOR THE TREATMENT OF ANKYLOSING SPONDYLITIS: A COST PER RESPONDER ANALYSIS AT 52 WEEKS FROM A BRAZILIAN PERSPECTIVE.
Lopes N1, Suzuki C1, Barbeau M2, MacPherson A3, Jugl SM4
1Novartis Biociências SA, Sao Paulo, Brazil, 2Novartis Pharmaceuticals Canada Inc., Dorval, QC, Canada, 3Dalhousie University, Halifax, NS, Canada, 4Novartis Pharma AG, Basel, Switzerland

PMS22
L18
SECUKINUMAB VS. ADALIMUMAB FOR THE TREATMENT OF PSORIATIC ARTHRITIS: A COST PER RESPONDER ANALYSIS AT 48 WEEKS FROM A BRAZILIAN PERSPECTIVE.
Lopes N1, Suzuki C1, Barbeau M2, MacPherson A3, Jugl SM4
1Novartis Biociências SA, Sao Paulo, Brazil, 2Novartis Pharmaceuticals Canada Inc., Dorval, QC, Canada, 3Dalhousie University, Halifax, NS, Canada, 4Novartis Pharma AG, Basel, Switzerland

PMS23
M1
COST-UTILITY ANALYSIS OF SECUKINUMAB USE VERSUS TNF-Α INHIBITORS, IN PATIENTS WITH ANKYLOSING SPONDILYTIS
Romero Prada ME, Roa Cardenas NC, Serrano GY, Huerfano LM
Salutia Foundation - Research center in economy, management and health technologies., Bogota, Colombia

PMS24
M2
FINANCIAL OPTIMIZATION IN THE TREATMENT FOR RHEUMATHOID ARTRITIS IN PATIENTS RECEIVING CONVENTIONAL DMARD THERAPY
Santos-Moreno P1, Villarreal Peralta L1, Jaimes H1, Jaimes J1, Buitrago-Garcia D2, Castro C2
1Biomab, center for rheumatoid arthritis, bogota, Colombia, 2SIIES investigation and research, Colombia, bogota, Colombia

MUSCULAR-SKELETAL DISORDERS - Patient-Reported Outcomes & Patient Preference Studies
PMS25
M3
SWITCHING OF BIOLOGICAL DRUGS IN RHEUMATOID ARTHRITIS: A COHORT OF USERS FROM THE BRAZILIAN PUBLIC HEALTH SYSTEM
Matute DL1, Galvao TF2, Mota LM3, Pereira MG4, Silva MT5
1Universidade Federal do Amazonas, Manaus, Brazil, 2Unicamp, Campinas, Brazil, 3University of Brasilia, Brasilia, Brazil, 4Universidade de Brasilia, Brasilia, Brazil, 5University of Sorocaba, Sorocaba, Brazil

PMS26
M4
HEALTH-RELATED QUALITY OF LIFE OF PATIENTS WITH OSTEOPOROSIS TREATED WITH TERIPARATIDE
Osca Guadalajara M1, Vivas Consuelo D2, Caballer Tarazona V2
1Hospital Obispo Polanco, Tereuel, Spain, 2Universitat Politècnica de València, Valencia, Spain

PMS27
M5
PATIENT-REPORTED OUTCOMES FROM PHASE 3 BARICITINIB RA-BEGIN STUDY: LATIN AMERICAN SUBGROUP ANALYSIS
Papadimitropoulos M1, Zerbini C2, Ramos-Remus C3, Martinez-Osuna P4, Zhu B4, Gaich CL4, Garcia EG5, Golcalves LF6
1Eli Lilly and Company, Canada and Assistant Professor, Faculty of Pharmacy, University of Toronto, Toronto, ON, Canada, 2Hospital das Clínicas University of São Paulo (USP), São Paulo, Brazil, 3Unidad de Investigacion en Enfermedades Cronico-Degenerativas, Mexico, Mexico, 4Eli Lilly and Company, Indianapolis, IN, USA, 5Eli Lilly and Company, Mexico City, Mexico, 6Eli Lilly and Company, Brazil, Brazil

PMS28
M6
PATIENT-REPORTED OUTCOMES FROM PHASE 3 BARICITINIB RA-BEAM STUDY: LATIN AMERICAN SUBGROUP ANALYSIS
Papadimitropoulos M1, Morales Ld2, Gonzaga JR3, Goncalves L4, Martinez-Osuna P5, Zhu B5, Gaich CL5, Garcia EG6
1Eli Lilly and Company, Canada and Assistant Professor, Faculty of Pharmacy, University of Toronto, Toronto, ON, Canada, 2Instituto Reumatológico Strusberg, Córdoba, Argentina, 3Centro de Investigacion Clinica Especializad, Mexico City, Mexico, 4Eli Lilly and Company, São Paulo, Brazil, 5Eli Lilly and Company, Indianapolis, IN, USA, 6Eli Lilly and Company, Mexico City, Mexico

PMS29
M7
WITHDRAWN

PMS30
M8
ASSESSING THE ECONOMIC AND HUMANISTIC BURDEN OF PSORIATIC ARTHRITIS IN BRAZIL
Lopes N1, Romiti R2, Pietri G3, Howe T3, Gilloteau I4, Tian H5, Barbeau M6, MacPherson A7
1Novartis Biociências SA, Sao Paulo, Brazil, 2Hospital das Clínicas University of São Paulo (USP), São Paulo, Brazil, 3GfK UK, London, UK, 4Novartis Pharma AG, Basel, Switzerland, 5Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA, 6Novartis Pharmaceuticals Canada Inc., Dorval, QC, Canada, 7Dalhousie University, Halifax, NS, Canada

PMS31
M9
ASSESSING THE BURDEN OF DISEASE IN PERIPHERAL AND AXIAL SPONDYLOARTHRITIS IN MEXICO AND BRAZIL
Romo X1, Piercy J2, Blackburn S2, Lopes N3, Jugl SM4, MacPherson A5, Barbeau M6
1Novartis Farmacéutica S.A. de C.V, Mexico City, Mexico, 2Adelphi Real World, Bollington, UK, 3Novartis Biociências SA, Sao Paulo, Brazil, 4Novartis Pharma AG, Basel, Switzerland, 5Dalhousie University, Halifax, NS, Canada, 6Novartis Pharmaceuticals Canada Inc., Dorval, QC, Canada

PMS32
M10
CALIDAD DE VIDA EN SALUD EN PACIENTES AMPUTADOS DE EXTREMIDAD INFERIOR CON PROTESIS DE UN HOSPITAL DE ESPECILIDAD PÚBLICO CHILENO
Cabrera M1, Lenz Alcayaga R2
1Universidad de Chile, Santiago, Chile, 2Lenz Consultores, Santiago, Chile

PMS33
M11
LONG-TERM WORK PRODUCTIVITY IMPROVEMENT FROM PHASE 3 BARICITINIB RA-BEAM STUDY: LATIN AMERICAN SUBGROUP ANALYSIS
Papadimitropoulos M1, Gonzaga JR2, Goncalves L3, Martinez-Osuna P4, Zhu B4, Gaich CL4, Garcia EG5
1Eli Lilly and Company, Canada; University of Toronto, Toronto, ON, Canada, 2Centro de Investigacion Clinica Especializad, Mexico City, Mexico, 3Eli Lilly and Company, São Paulo, Brazil, 4Eli Lilly and Company, Indianapolis, IN, USA, 5Eli Lilly and Company, Mexico City, Mexico

MUSCULAR-SKELETAL DISORDERS - Health Care Use & Policy Studies
PMS34
M12
OUTCOMES OF DISEASE ACTIVITY IN RHEUMATOID ARTHRITIS AND HEALTH INSURANCE: RESULTS FROM REAL WORLD
Valencia O, Sanchez P, Acuña L, Bermúdez NC, Uribe Parra D, Pulido DC
Fondo Colombiano de Enfermedades de Alto Costo, Bogotá, Colombia

PMS35
M13
FEDERAL SPENDING ON INFLIXIMAB IN BRAZIL: AN ANALYSIS OF PURCHASES FROM 2007-2015
Santana PK1, Steffen RE1, Osorio-de-Castro CG2, Caetano R3
1Social Medicine Institute/UERJ, Rio de Janeiro, Brazil, 2Sergio Arouca National School of Public Health,Oswaldo Cruz Foundation, Rio de Janeiro, Brazil, 3Instituto de Medicina Social, Universidade do Estado do Rio de Janeiro, Rio de Janeiro, Brazil, Rio de Janeiro, Brazil

PMS36
N1
PATTERNS OF BIOLOGICAL THERAPY USE IN PATIENTS WITH RHEUMATOID ARTRHITIS IN A REAL-LIFE SETTING IN COLOMBIA
Santos-Moreno P1, Villarreal Peralta L1, Jaimes H1, Jaimes J1, Buitrago-Garcia D2, Castro C2
1Biomab, center for rheumatoid arthritis, bogota, Colombia, 2SIIES investigation and research, Colombia, bogota, Colombia

PMS37
N2
CHARACTERISITCS OF PATIENTS RECEIVING LEFLUNOMIDE, METHOTREXATE OR LEFLUNOMIDE PLUS METHOTREXATE FOR THE TREATMENT OF RHEUMATOID ARTHRITIS IN A REAL-LIFE SETTING IN COLOMBIA
Santos-Moreno P1, Villarreal Peralta L1, Jaimes H1, Jaimes J1, Buitrago-Garcia D2, Castro C2
1Biomab, center for rheumatoid arthritis, bogota, Colombia, 2SIIES investigation and research, Colombia, bogota, Colombia

PMS38
N3
STATISTICS AND COSTS OF EMERGENCY CARE RELATED TO EXTERNAL CAUSES IN ONE HOSPITAL OF RIO DE JANEIRO CITY
Fernandes RA1, Sauberman MV2, Bejder Dd2, Amaral LM1, Vasconcellos JF1, Souza CP1, Teich V3
1Sense Company, Rio de Janeiro, Brazil, 2Hospital Municipal Lourenço Jorge, Rio de Janeiro, Brazil, 3Sense Company, São Paulo, Brazil

PMS39
N4
COMPARISON OF HEALTH TECHNOLOGY ASSESSMENTS IN RHEUMATOLOGY FROM 2012 TO 2016
Farinasso C1, Laranjeira FO2, Pereira MG1
1Universidade de Brasilia, Brasilia, Brazil, 2Universidade de Brasilia, BRASILIA, Brazil

Contact ISPOR @ info@ispor.org | View Legal Disclaimer
© 2018 International Society for Pharmacoeconomics and Outcomes Research.
All rights reserved under International and Pan-American Copyright Conventions.